- Home
- YXT vs NOTV Comparison
YXT vs NOTV Comparison
Compare YXT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- NOTV
- Stock Information
- Founded
- YXT 2011
- NOTV 1974
- Country
- YXT China
- NOTV United States
- Employees
- YXT N/A
- NOTV N/A
- Industry
- YXT
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- NOTV Health Care
- Exchange
- YXT NYSE
- NOTV Nasdaq
- Market Cap
- YXT 129.2M
- NOTV 126.3M
- IPO Year
- YXT 2024
- NOTV 1997
- Fundamental
- Price
- YXT $2.03
- NOTV $4.56
- Analyst Decision
- YXT
- NOTV Strong Buy
- Analyst Count
- YXT 0
- NOTV 3
- Target Price
- YXT N/A
- NOTV $5.92
- AVG Volume (30 Days)
- YXT 94.4K
- NOTV 893.2K
- Earning Date
- YXT 02-21-2025
- NOTV 02-05-2025
- Dividend Yield
- YXT N/A
- NOTV N/A
- EPS Growth
- YXT N/A
- NOTV N/A
- EPS
- YXT 3.06
- NOTV N/A
- Revenue
- YXT $48,030,651.00
- NOTV $490,739,000.00
- Revenue This Year
- YXT N/A
- NOTV $7.14
- Revenue Next Year
- YXT N/A
- NOTV $5.73
- P/E Ratio
- YXT $0.65
- NOTV N/A
- Revenue Growth
- YXT N/A
- NOTV N/A
- 52 Week Low
- YXT $1.82
- NOTV $1.23
- 52 Week High
- YXT $11.00
- NOTV $11.42
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- NOTV 53.20
- Support Level
- YXT N/A
- NOTV $3.87
- Resistance Level
- YXT N/A
- NOTV $4.67
- Average True Range (ATR)
- YXT 0.00
- NOTV 0.53
- MACD
- YXT 0.00
- NOTV -0.08
- Stochastic Oscillator
- YXT 0.00
- NOTV 38.33
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.